Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Exp Neurol ; 333: 113398, 2020 11.
Article in English | MEDLINE | ID: mdl-32659382

ABSTRACT

We investigated the ability of agmatine to potentiate the antidepressant-like and synaptic effects of ketamine in mice. Agmatine (0.1 and 1 mg/kg, p.o.) and ketamine (1 and 10 mg/kg, i.p.) produced an antidepressant-like effect in the tail suspension test. The combination of agmatine (0.01 mg/kg, p.o.) and ketamine (0.1 mg/kg, i.p.), at subthreshold doses, produced an antidepressant-like effect 1 h, 24 h and 7d after treatment. Western blot analysis from prefrontal cortex tissue showed that the combined treatment, after 1 h, increased p70S6K and GluA1, and reduced synapsin 1 phosphorylation. Additionally, after 24 h, Akt, p70S6K, GluA1, and synapsin 1 phosphorylation; and PSD95 immunocontent increased (which persisted for up to 7d). Dendritic architecture analysis of the prefrontal cortex revealed that the combined treatment improved dendritic arbor complexity (after 24 h, up to 7d), and increased spine density (after 1 h, up to 24 h). Morphometric analysis revealed a filopodia-shaped dendrite spine upregulation after 1 h. A predominance of stubby, mushroom, branched and filopodia; and a reduction in thin protrusions were observed after 24 h. Finally, mushroom-shaped dendritic spines predominance increased after 7d. Agmatine potentiated ketamine's antidepressant, and dendritic arbors and spines remodeling effects in a time-dependent manner. Our data indicate Akt/p70S6K signaling as a likely target for these effects.


Subject(s)
Agmatine/pharmacology , Antidepressive Agents/pharmacology , Dendrites/drug effects , Dendritic Spines/drug effects , Ketamine/pharmacology , Oncogene Protein v-akt/drug effects , Ribosomal Protein S6 Kinases/drug effects , Signal Transduction/drug effects , Synapses/drug effects , Animals , Dendrites/ultrastructure , Dendritic Spines/ultrastructure , Drug Synergism , Hindlimb Suspension , Male , Mice , Motor Activity/drug effects , Prefrontal Cortex/drug effects
2.
J Psychiatr Res ; 100: 16-23, 2018 05.
Article in English | MEDLINE | ID: mdl-29475017

ABSTRACT

Some studies have demonstrated that ascorbic acid, similarly to ketamine, exhibits antidepressant-like effects mediated, at least in part, by modulation of the glutamatergic system. Despite the involvement of glutamatergic system in the pathophysiology of anxiety disorders, the ability of ascorbic acid and ketamine to elicit anxiolytic effects in animal models remains to be established. Therefore, this study investigated the effects of a single administration of ascorbic acid, ketamine or diazepam (positive control) in different animal models of anxiety. Mice were treated with ascorbic acid (1, 3 and 10 mg∕kg, p.o.), ketamine (1 and 10 mg∕kg, i.p.) or diazepam (2 mg∕kg, p.o) and their behavioral responses were assessed in the elevated plus maze, open field test (OFT), ligh∕dark preference test and marble burying test. Ascorbic acid increased total time spent in the open arms of elevated plus maze, increased total time in the center of the OFT, decreased rearing responses, increased the latency to grooming, decreased the rostral grooming, but did not affect body grooming. Furthermore, ascorbic acid increased the latency time and total time in light area in the ligh∕dark preference test, but did not affect the performance of mice in the marble burying test. Ketamine demonstrated an anxiolytic-like effect in elevated plus maze, OFT, and ligh∕dark preference test. Diazepam exhibited an anxiolytic-like effect in all the behavioral tests. Altogether, the results indicate the potential anxiolytic effect of ascorbic acid and ketamine, providing a possible new avenue for the management of anxiety-related disorders.


Subject(s)
Anti-Anxiety Agents/pharmacology , Anxiety/drug therapy , Ascorbic Acid/pharmacology , Behavior, Animal/drug effects , Ketamine/pharmacology , Animals , Anti-Anxiety Agents/administration & dosage , Ascorbic Acid/administration & dosage , Diazepam/pharmacology , Disease Models, Animal , Female , Ketamine/administration & dosage , Mice
3.
Article in English | MEDLINE | ID: mdl-28842257

ABSTRACT

Agmatine is an endogenous neuromodulator that has been shown to have beneficial effects in the central nervous system, including antidepressant-like effects in animals. In this study, we investigated the ability of agmatine (0.1mg/kg, p.o.) and the conventional antidepressant fluoxetine (10mg/kg, p.o.) to reverse the behavioral effects and morphological alterations in the hippocampus of mice exposed to chronic corticosterone (20mg/kg, p.o.) treatment for a period of 21days as a model of stress and depressive-like behaviors. Chronic corticosterone treatment increased the immobility time in the tail suspension test (TST), but did not cause anhedonic-like and anxiety-related behaviors, as assessed with the splash test and the open field test (OFT), respectively. Of note, the depressive-like behaviors induced by corticosterone were accompanied by a decrease in hippocampal cell proliferation, although no changes in hippocampal neuronal differentiation were observed. Our findings provide evidence that, similarly to fluoxetine, agmatine was able to reverse the corticosterone-induced depressive-like behaviors in the TST as well as the deficits in hippocampal cell proliferation. Additionally, fluoxetine but not agmatine, increased hippocampal differentiation. Agmatine, similar to fluoxetine, was capable of increasing both dendritic arborization and length in the entire dentate hippocampus, an effect more evident in the ventral portion of the hippocampus, as assessed with the modified Sholl analysis. Altogether, our results suggest that the increase in hippocampal proliferation induced by agmatine may contribute, at least in part, to the antidepressant-like response of this compound in this mouse model of stress induced by chronic exposure to corticosterone.


Subject(s)
Agmatine/pharmacology , Antidepressive Agents/pharmacology , Hippocampus/drug effects , Stress, Psychological/drug therapy , Anhedonia/drug effects , Anhedonia/physiology , Animals , Cell Proliferation/drug effects , Cell Proliferation/physiology , Corticosterone , Depressive Disorder/drug therapy , Depressive Disorder/pathology , Depressive Disorder/physiopathology , Disease Models, Animal , Female , Fluoxetine/pharmacology , Hippocampus/pathology , Hippocampus/physiopathology , Mice , Motor Activity/drug effects , Neurogenesis/drug effects , Neurogenesis/physiology , Neuronal Plasticity/drug effects , Neuronal Plasticity/physiology , Random Allocation , Stress, Psychological/pathology , Stress, Psychological/physiopathology
4.
Mol Neurobiol ; 54(8): 6245-6260, 2017 Oct.
Article in English | MEDLINE | ID: mdl-27714631

ABSTRACT

The benefits of creatine supplementation have been reported in a broad range of central nervous system diseases, including depression, although the mechanisms underlying these effects remain to be understood. In the present study, we investigated the ability of creatine to counteract the morphological and behavioral effects elicited by chronic administration of corticosterone (CORT, 20 mg/kg, p.o.) for 21 days to mice, a pharmacological model of depression that mimics exposure to stress. CORT treatment increased immobility time in the tail suspension test (TST) and forced swim test (FST), as well as latency to immobility in the FST, and decreased the sucrose consumption in the sucrose preference test (SPT). These behavioral effects were associated with decreased hippocampal cell proliferation and neuronal differentiation and increased glial fibrillary acid protein (GFAP) immunostaining (suggestive of astrogliosis) in dentate gyrus (DG) of the hippocampus. These CORT-induced alterations were abolished by treatment with either fluoxetine (a conventional antidepressant) or creatine for 21 days (both 10 mg/kg, p.o.). In addition, fluoxetine, but not creatine, was able to reverse the CORT-induced reduction in serum CORT levels. Collectively, our results suggest that creatine produces morphological alterations that contribute to the improvement of depressive-like behaviors triggered by chronic CORT administration in mice.


Subject(s)
Antidepressive Agents/pharmacology , Cell Differentiation/drug effects , Cell Proliferation/drug effects , Corticosterone/pharmacology , Creatine/pharmacology , Hippocampus/drug effects , Animals , Antidepressive Agents/therapeutic use , Behavior, Animal/drug effects , Creatine/therapeutic use , Depression/drug therapy , Feeding Behavior/drug effects , Female , Fluoxetine/pharmacology , Glial Fibrillary Acidic Protein/metabolism , Hippocampus/cytology , Hippocampus/metabolism , Mice , Motor Activity/drug effects , Neurons/cytology , Neurons/drug effects , Neurons/metabolism , Sucrose
SELECTION OF CITATIONS
SEARCH DETAIL
...